Breast Cancer Cell Subtypes Display Different Metabolic Phenotypes That Correlate with Their Clinical Classification
Metadata
Show full item recordAuthor
Ripoll, Consuelo; Roldan, Mar; Ruedas Rama, María José; Orte Gutiérrez, Ángel; Martín Hernández, MiguelEditorial
MPDI
Materia
Metabolic profiling Breast cancer Tumor metabolism Metabolic reprogramming
Date
2021Referencia bibliográfica
Ripoll, C.; Roldan, M.; Ruedas-Rama, M.J.; Orte, A.; Martin, M. Breast Cancer Cell Subtypes Display Different Metabolic Phenotypes That Correlate with Their Clinical Classification. Biology 2021, 10, 1267. https://doi.org/10.3390/ biology10121267
Sponsorship
Spanish Agencia Estatal de Investigación (Ministry of Science and Innovation); European Regional Development Fund [grant numbers CTQ2014-56370-R and CTQ2017-85658-R]; Fundación Ramón Areces; Initiative "Solidaridad Entre Montañas"Abstract
Recent studies on cancer cell metabolism have achieved notable breakthroughs
that have led to a new scientific paradigm. How cancer cell metabolic reprogramming is orchestrated
and the decisive role of this reprogramming in the oncogenic process and tumor adaptative evolution
has been characterized at the molecular level. Despite this knowledge, it is essential to understand
how cancer cells can metabolically respond as a living whole to ensure their survival and adaptation
potential. In this work, we investigated whether different cancers and different subtypes display
different metabolic phenotypes with a focus on breast cancer cell models representative of each
clinical subtype. The potential results might have significant translational implications for diagnostic,
prognostic and therapeutic applications. Metabolic reprogramming of cancer cells represents an orchestrated network of evolving
molecular and functional adaptations during oncogenic progression. In particular, how metabolic reprogramming is orchestrated in breast cancer and its decisive role in the oncogenic process and tumor
evolving adaptations are well consolidated at the molecular level. Nevertheless, potential correlations
between functional metabolic features and breast cancer clinical classification still represent issues
that have not been fully studied to date. Accordingly, we aimed to investigate whether breast cancer
cell models representative of each clinical subtype might display different metabolic phenotypes
that correlate with current clinical classifications. In the present work, functional metabolic profiling
was performed for breast cancer cell models representative of each clinical subtype based on the
combination of enzyme inhibitors for key metabolic pathways, and isotope-labeled tracing dynamic
analysis. The results indicated the main metabolic phenotypes, so-called ‘metabophenotypes’, in
terms of their dependency on glycolytic metabolism or their reliance on mitochondrial oxidative
metabolism. The results showed that breast cancer cell subtypes display different metabophenotypes.
Importantly, these metabophenotypes are clearly correlated with the current clinical classifications.